Fill and Finish Biologics: What Matters and What Doesn’t
Capabilities
When developing biologics, fill & finish has the potential to either break or scale the process. Sterility, tight dosing, and regulatory readiness are crucial and hold the risks of increasing time, money.
Pharmaron provides a real end-to-end fill and finish biologics platform, covering integrated formulation, aseptic manufacturing, lyophilization, and prefilled systems with a focus on speed, control, and reduced timelines.
Focusing on Fill and Finish Biologics:
Aseptic Sterile Manufacturing That Scales
- Uses RABS (Restricted Access Barrier Systems) and oRABS
- Real-time weight checks for narrow therapeutic index drugs
- Designed for biologics that can’t tolerate contamination or temperature swings
- Built to meet global current Good Manufacturing Practice (cGMP) standards
Container Flexibility (That’s Been Validated)
- Vials: both liquid and lyophilized
- Pre-filled syringes (PFS): for high-precision dosing
- Cartridges: for device-compatible therapies
Lyophilization That Doesn’t Ruin Stability
- Runs thermal analysis (Tg’, Tc) before freeze-drying
- Maintains product structure and bioactivity
- Scales without reformulation risk
Inline Testing Built Into the Process
- Sterile filter integrity testing during production
- In-process monitoring to catch batch variation early
- Keeps sterility assurance high without needing add-on QC cycles
Commercial-Grade Throughput
- Up to 10,000 vials/hour
- Up to 8,000 PFS/hour
- Clinical to commercial without needing a tech transfer
Development Approach That Reduces Hand-offs
Instead of sourcing formulation from one vendor and sterile fill from another, Pharmaron offers a single integrated workflow:
- Formulation: For both liquid and lyophilized formats
- Process Development: Optimization from R&D through commercial scale
- In-Use Studies: To confirm compatibility with administration protocols
- Particle Analysis: Prevents aggregation and ensures USP <788> compliance
References:
- Injectables-related USP Documentary Standards
- EU Commission – Annex 1 – Manufacture of Sterile Medicinal Products
- FDA – Sterile Drug Products Produced by Aseptic Processing
- WHO Annex 6 – GMP for Sterile Pharmaceutical Products
Why Download the Service Overview
If you’re evaluating CDMOs for biologics, download the brochure to get actual numbers, specs, and workflows. Skip vague marketing. See if Pharmaron’s setup fits your pipeline without unnecessary risk or delay.